Arbutus Biopharma Corporation

(NASDAQ:ABUS)

Latest On Arbutus Biopharma Corporation (ABUS):

Date/Time Type Description Signal Details
2023-05-18 02:45 ESTNewsArbutus: Two Data Readouts Of AB-729 Could Shift Momentum In 2023N/A
2023-05-04 21:46 ESTNewsArbutus Biopharma Corporation (ABUS) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 08:45 ESTNewsArbutus Biopharma GAAP EPS of -$0.10 beats by $0.04, revenue of $6.7M beats by $0.67MN/A
2023-04-25 14:16 ESTNewsArbutus sheds 18% after FDA clinical hold on antiviralN/A
2023-04-12 00:01 ESTNewsModerna wins appeals court ruling in Arbutus COVID vaccine patent disputeN/A
2023-04-05 02:46 ESTNewsPfizer, BioNTech dip as Arbutus charges violation of COVID vaccine patentsN/A
2023-03-02 12:31 ESTNewsArbutus Biopharma GAAP EPS of -$0.46 misses by $0.33, revenue of $39M beats by $32.88MN/A
2023-03-02 12:30 ESTNewsArbutus Biopharma Corporation (ABUS) Q4 2022 Earnings Call TranscriptN/A
2023-03-01 22:16 ESTNewsArbutus Biopharma FY 2022 Earnings PreviewN/A
2023-02-23 11:16 ESTNewsArbutus Biopharma Corp.: Long Road Ahead For HBV CureN/A
2022-11-09 19:33 ESTNewsArbutus Biopharma GAAP EPS of -$0.12 beats by $0.01, revenue of $5.95M misses by $3.23MN/A
2022-11-09 19:32 ESTNewsArbutus Biopharma Corporation (ABUS) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 19:32 ESTNewsArbutus trades higher as Q3 net loss narrows, revenue grows on license dealN/A
2022-11-07 14:15 ESTNewsArbutus Biopharma (ABUS) presents at AASLD 2022 - SlideshowN/A
2022-11-03 05:01 ESTNewsArbutus gains after court denies Moderna motion to dismiss Covid-19 royalties caseN/A
2022-09-12 13:02 ESTNewsArbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'N/A
2022-08-30 16:31 ESTNewsArbutus stock rises on US patent linked to hepatitis B therapy AB-729N/A
2022-08-04 22:47 ESTNewsArbutus Biopharma GAAP EPS of -$0.10 beats by $0.03, revenue of $14.24M beats by $7.47MN/A
2022-08-04 22:46 ESTNewsArbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-03 16:46 ESTNewsArbutus Biopharma Q2 2022 Earnings PreviewN/A
2022-07-20 18:00 ESTNewsArbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trialN/A
2022-06-30 05:46 ESTNewsArbutus: 2 Key Catalysts To Look Forward To After EASL Data ReleaseN/A
2022-06-06 15:46 ESTNewsArbutus and Vaccitech begin trial testing combo therapy for chronic hepatitis B virus treatmentN/A
2022-05-05 20:18 ESTNewsArbutus Biopharma GAAP EPS of -$0.11 beats by $0.05, revenue of $12.58M beats by $8.16MN/A
2022-05-05 20:16 ESTNewsArbutus Biopharma Corp (ABUS) CEO William Collier on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 21:31 ESTNewsArbutus Biopharma Q1 2022 Earnings PreviewN/A
2022-03-19 19:34 ESTNewsArbutus sued to avoid patent dispute over Pfizer/BioNTech COVID-19 shotN/A
2022-03-14 23:02 ESTNewsArbutus price target raised at H.C. Wainwright on upcoming data readoutsN/A
2022-03-08 08:32 ESTNewsArbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of InterestN/A
2022-03-04 00:32 ESTNewsArbutus Biopharma GAAP EPS of -$0.83 beats by $0.03, revenue of $11M beats by $0.35MN/A
2022-03-04 00:31 ESTNewsArbutus Biopharma Corporation 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-04 00:31 ESTNewsArbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-02 12:45 ESTNewsArbutus Biopharma Q4 2021 Earnings PreviewN/A
2022-03-01 02:17 ESTNewsModerna hit by lawsuit as Arbutus, Genevant seek damages for use of COVID-19 vaccine patentsN/A
2022-01-24 16:17 ESTNewsArbutus Biopharma outlines milestones for 2022N/A
2021-12-22 11:31 ESTNewsRoivant Sciences Nearly Doubles Since Moderna Patent Ruling, Buy ArbutusN/A
2021-12-17 17:31 ESTNewsArbutus Biopharma: How Will Patent Win Impact Stock Outlook?N/A
2021-12-13 14:32 ESTNewsArbutus in up to $300M deal with Qilu in China for hepatitis B candidate; shares up 7%N/A
2021-12-08 01:33 ESTNewsArbutus identifies molecular targets for COVID-19 treatmentN/A
2021-12-01 16:46 ESTNewsModerna loses patent fight against Arbutus related to vaccines; Arbutus up 40%N/A
2021-12-01 16:46 ESTNewsArbutus chronic hepatitis B virus treatment shows antiviral activity in early-stage trialN/A
2021-12-01 16:46 ESTNewsRoivant Sciences benefits from Arbutus patent win over Moderna; shares up 37%N/A
2021-11-20 03:16 ESTNewsArbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive InvestmentN/A
2021-11-19 06:32 ESTNewsAlnylam, Arrowhead gain on Novo bid to acquire DicernaN/A
2021-11-05 00:18 ESTNewsArbutus Biopharma EPS in-line, beats on revenueN/A
2021-11-05 00:16 ESTNewsArbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 03:02 ESTNewsArbutus Biopharma Q3 2021 Earnings PreviewN/A
2021-10-09 16:30 ESTNewsA look at the biopharmas developing new treatments for liver diseasesN/A
2021-10-07 03:30 ESTNewsModerna slips ahead of legal battle to invalidate COVID-19 vaccine patentsN/A
2021-09-22 20:29 ESTNewsArbutus Biopharma (ABUS) Investor Presentation - SlideshowN/A

About Arbutus Biopharma Corporation (ABUS):

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

See Advanced Chart

General

  • Name Arbutus Biopharma Corporation
  • Symbol ABUS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 76
  • Last Split Factor1:5
  • Last Split Date2010-11-04
  • Fiscal Year EndDecember
  • IPO Date2015-08-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.arbutusbio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 40.69
  • Price/Book (Most Recent Quarter) 2.44
  • Enterprise Value Revenue 56.13
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.86
  • Next Year EPS Estimate -$0.67
  • Next Quarter EPS Estimate -$0.23
  • Operating Margin -828%
  • Return on Assets -30%
  • Return on Equity -73%
  • Revenue 6.91 million
  • Earnings Per Share -$1.79
  • Revenue Per Share $0.09
  • Gross Profit -40567000
  • Quarterly Earnings Growth 47.5%
View More

Highlights

  • Market Capitalization 349.26 million
  • EBITDA -71643000
  • PE Ratio -9.48
  • Analyst Target Price $6.11
  • Book Value Per Share $1.23
View More

Share Statistics

  • Shares Outstanding 95.58 million
  • Shares Float 69.81 million
  • % Held by Insiders 2123%
  • % Held by Institutions 30.96%
  • Shares Short 3.27 million
  • Shares Short Prior Month 2.55 million
  • Short Ratio 0.94
  • Short % of Float 5%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 3.05
  • 52 Week High $6.48
  • 52 Week Low $0.88
  • 50 Day Moving Average 3.96
  • 200 Day Moving Average 3.56
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Arbutus Biopharma Corporation (ABUS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Arbutus Biopharma Corporation (ABUS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$2.39 million-$0.23-$0.22-2.74%
2020-09-302020-11-05$N/A-$0.27-$0.22-26.07%
2020-06-302020-08-07$N/A-$0.25-$0.24-1.59%
2020-03-312020-05-11$1.49 million-$0.25-$0.3120.71%
2019-12-312020-03-05$1.62 million-$0.46-$0.36-26.6%
2019-09-302019-11-06$3.06 million-$1.50-$0.34-346.17%
2019-06-302019-08-05$653000-$0.46-$0.38-22.19%
2019-03-312019-05-06$679000-$0.47-$0.32-46.41%
2018-12-312019-03-07$1.68 million-$0.37-$0.406.98%
2018-09-302018-11-07$1.59 million-$0.49-$0.41-19.75%
2018-06-302018-08-02$1.24 million$0.01-$0.39102.54%
2018-03-312018-05-03$1.44 million-$0.36-$0.4010.76%
2017-12-312018-03-14$2.53 million-$0.67-$0.38-73.97%
2017-09-302017-11-02$6.89 million-$0.21-$0.3540.78%
2017-06-302017-08-03$1.04 million-$0.33-$0.4221.27%
2017-03-312017-05-04$235000-$0.34-$0.30-12.68%
2016-12-312017-03-21$-195000-$4.08-$0.40-932.74%
2016-09-302016-11-03$774000-$0.37-$0.5025.5%
2016-06-302016-08-04$309000-$2.47-$0.39-528.02%
2016-03-312016-05-04$603000-$0.31-$0.3716.46%
2015-12-312016-03-09$15.26 million-$0.10-$0.3974.17%
2015-09-302015-11-05$4.07 million-$0.12-$0.2958.62%
2015-06-302015-08-07$869000-$0.27-$0.296.9%
2015-03-312015-05-06$4.68 million-$0.40-$0.36-11.11%
2014-12-312015-03-12$4.35 million-$0.27-$0.283.57%
2014-09-302014-11-06$4.36 million-$0.39-$0.31-25.81%
2014-06-302014-08-13$1.81 million-$0.28-$0.25-12%
2014-03-312014-05-14$4.43 million-$0.91$0.16-668.75%
2013-12-312014-03-06$7.51 million-$0.10$0.06-266.67%
2013-09-302013-11-13$2.96 million-$0.42-$0.21-100%
2013-06-302013-08-12$2.79 million-$0.21
2013-03-312013-05-14$2.16 million-$0.18
2012-12-312013-03-27$3.91 million$2.70
2012-09-302012-11-13$3.1 million-$0.25
2012-06-302012-08-14$3.56 million-$0.14-$0.1612.5%
2012-03-312012-05-15$3.6 million-$0.25-$0.17-47.06%
2011-12-312012-03-27$3.66 million-$0.15
2011-09-302011-11-08$3.96 million-$0.12-$0.3060%
2011-06-302011-08-11$4.58 million-$0.33-$0.30-10%
2011-03-312011-05-10$4.48 million-$0.30-$0.3616.67%
2010-12-312011-03-30$6.21 million-$0.20-$0.2520%
2010-09-302010-11-15$4.34 million-$1.09-$0.20-445%
2010-06-302010-08-12$2.18 million-$0.40-$0.35-14.29%
2009-12-312010-03-17$4.27 million-$0.25-$0.3016.67%
2009-06-302009-08-12$3.25 million-$0.20-$0.15-33.33%
2009-03-312009-05-13$2.28 million-$0.20-$0.2520%
2008-12-312009-03-24$2.53 million-$0.35-$0.5030%
2007-12-312008-03-30$4.22 million$0.10$0.05100%
2007-09-302007-11-14$5.76 million$0.30$0.45-33.33%
2007-06-302007-08-08$2.82 million-$1.05-$0.30-250%

Arbutus Biopharma Corporation (ABUS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Arbutus Biopharma Corporation (ABUS) Chart:

Arbutus Biopharma Corporation (ABUS) News:

Below you will find a list of latest news for Arbutus Biopharma Corporation (ABUS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Arbutus Biopharma Corporation (ABUS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-2010CALL0 01068.89TRUE00
2025-06-2020CALL0 18546.61TRUE00
2025-06-2030.57CALL0 254763.1TRUE00
2025-06-2040.05CALL0 1102183.78FALSE00
2025-06-2050CALL0 590125.92FALSE00
2025-06-2060CALL0 106252.72FALSE00
2025-06-2070CALL0 30346.9FALSE00
2025-06-2010PUT0 0747.98FALSE00
2025-06-2020PUT0 0378.74FALSE00
2025-06-2030PUT0 2520110.3FALSE00
2025-06-2040PUT0 166101.13TRUE00
2025-06-2050PUT0 0222.36TRUE00
2025-06-2060PUT0 0251.15TRUE00
2025-06-2070PUT0 0265.9TRUE00
2025-07-1810CALL0 0508.74TRUE00
2025-07-1820CALL0 0388.03TRUE00
2025-07-1830CALL0 095.56TRUE00
2025-07-1840.11CALL0 44953.47FALSE00
2025-07-1850CALL0 0166.59FALSE00
2025-07-1860CALL0 0198.6FALSE00
2025-07-1810PUT0 0483.99FALSE00
2025-07-1820PUT0 0245.39FALSE00
2025-07-1830PUT0 084.04FALSE00
2025-07-1840PUT0 079.03TRUE00
2025-07-1850PUT0 0134.13TRUE00
2025-07-1860PUT0 0165.37TRUE00
2025-08-150.50CALL0 0684.02TRUE00
2025-08-1510CALL0 0403.55TRUE00
2025-08-151.50CALL0 0344.19TRUE00
2025-08-1520CALL0 20368.49TRUE00
2025-08-152.50CALL0 99338.1TRUE00
2025-08-1530CALL0 10984.24TRUE00
2025-08-153.50.25CALL0 218460.82FALSE00
2025-08-1540.19CALL0 281774.7FALSE00
2025-08-154.50CALL0 7179.88FALSE00
2025-08-1550CALL0 65283.88FALSE00
2025-08-155.50CALL0 0171.32FALSE00
2025-08-1560CALL0 10179.22FALSE00
2025-08-1570CALL0 4152.81FALSE00
2025-08-150.50PUT0 0708.87FALSE00
2025-08-1510PUT0 0385.57FALSE00
2025-08-151.50PUT0 0268.66FALSE00
2025-08-1520PUT0 0195.74FALSE00
2025-08-152.50PUT0 4694.71FALSE00
2025-08-1530PUT0 3457.86FALSE00
2025-08-153.50.44PUT0 219246.63TRUE00
2025-08-1540PUT0 1114.84TRUE00
2025-08-154.51.13PUT0 1118.88TRUE00
2025-08-1550PUT0 0135.6TRUE00
2025-08-155.50PUT0 0149.8TRUE00
2025-08-1560PUT0 0123.29TRUE00
2025-08-1570PUT0 0163.96TRUE00
2025-09-1910CALL0 0452.24TRUE00
2025-09-1920CALL0 5317.63TRUE00
2025-09-1930.65CALL2 101660.83TRUE0.650
2025-09-1940.25CALL0 10985.39FALSE00
2025-09-1950CALL0 69986.12FALSE00
2025-09-1960CALL0 1158.29FALSE00
2025-09-1970CALL0 0146.14FALSE00
2025-09-1910PUT0 0320.01FALSE00
2025-09-1920PUT0 0133.07FALSE00
2025-09-1930PUT0 104468.22FALSE00
2025-09-1940PUT0 8046.78TRUE00
2025-09-1950PUT0 079.27TRUE00
2025-09-1960PUT0 0121.2TRUE00
2025-09-1970PUT0 081.61TRUE00
2025-10-1710CALL0 0403.73TRUE00
2025-10-1720CALL0 29295.7TRUE00
2025-10-1730CALL0 101653.54TRUE00
2025-10-1740.47CALL3 353781.31FALSE0.470
2025-10-1750CALL0 737283.36FALSE00
2025-10-1760.25CALL0 149101.89FALSE00
2025-10-1770CALL0 13112.33FALSE00
2025-10-1780CALL0 0158.97FALSE00
2025-10-1710PUT0 0341.19FALSE00
2025-10-1720PUT0 0113.84FALSE00
2025-10-1730PUT0 100082.13FALSE00
2025-10-1740PUT0 35942.75TRUE00
2025-10-1750PUT0 699.86TRUE00
2025-10-1760PUT0 070.84TRUE00
2025-10-1770PUT0 0121.81TRUE00
2025-10-1780PUT0 086.52TRUE00
2025-12-1910CALL0 0334.14TRUE00
2025-12-1920CALL0 0255.03TRUE00
2025-12-1930CALL0 0319.59TRUE00
2025-12-1940CALL0 3094.75FALSE00
2025-12-1950CALL0 27584.78FALSE00
2025-12-1960.25CALL0 52792.54FALSE00
2025-12-1970CALL0 50289.44FALSE00
2025-12-1910PUT0 0239.07FALSE00
2025-12-1920PUT0 099.89FALSE00
2025-12-1930PUT0 3774.92FALSE00
2025-12-1940PUT0 042.72TRUE00
2025-12-1950PUT0 0113.28TRUE00
2025-12-1960PUT0 093.87TRUE00
2025-12-1970PUT0 0107.32TRUE00
2026-01-160.50CALL0 0225.49TRUE00
2026-01-1610CALL0 5221.27TRUE00
2026-01-161.50CALL0 0242.22TRUE00
2026-01-1620CALL0 7487.46TRUE00
2026-01-162.50CALL0 4192.4TRUE00
2026-01-1630CALL0 134257.41TRUE00
2026-01-163.50CALL0 16390.35FALSE00
2026-01-1640CALL0 39335.73FALSE00
2026-01-164.50CALL0 61281.21FALSE00
2026-01-1650CALL0 22674.24FALSE00
2026-01-165.50.4CALL25 25284.71FALSE00
2026-01-1660CALL0 0286.89FALSE00
2026-01-1670CALL0 495.12FALSE00
2026-01-160.50PUT0 0414.11FALSE00
2026-01-1610PUT0 0224.57FALSE00
2026-01-161.50PUT0 0118.05FALSE00
2026-01-1620PUT0 093.97FALSE00
2026-01-162.50PUT0 086.7FALSE00
2026-01-1630PUT0 1573.36FALSE00
2026-01-163.50PUT0 10058.08TRUE00
2026-01-1640PUT0 1540.68TRUE00
2026-01-164.50PUT0 10087.11TRUE00
2026-01-1650PUT0 0121.23TRUE00
2026-01-165.50PUT0 0125.48TRUE00
2026-01-1660PUT0 183.49TRUE00
2026-01-1670PUT0 083.35TRUE00
2027-01-152.51.5CALL1 2764.35TRUE1.50
2027-01-1530CALL0 0169.14TRUE00
2027-01-153.50CALL0 13176.83FALSE00
2027-01-1540CALL0 2664.36FALSE00
2027-01-154.50CALL0 0188.47FALSE00
2027-01-1550CALL0 1261.86FALSE00
2027-01-155.50.7CALL0 22972.96FALSE00
2027-01-1570CALL0 6371.72FALSE00
2027-01-152.50PUT0 069.34FALSE00
2027-01-1530PUT0 1682.52FALSE00
2027-01-153.50PUT0 453.63TRUE00
2027-01-1540PUT0 044.79TRUE00
2027-01-154.50PUT0 034.15TRUE00
2027-01-1550PUT0 0106.25TRUE00
2027-01-155.50PUT0 090.77TRUE00
2027-01-1570PUT0 096.56TRUE00

Latest ABUS Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST400$2.39
Jun 13, 2022 7:59 PM EST200$2.39
Jun 13, 2022 7:59 PM EST1000$2.39
Jun 13, 2022 7:59 PM EST200$2.385
Jun 13, 2022 7:59 PM EST17$2.385

Arbutus Biopharma Corporation (ABUS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000073/0001447028-20-000073-index.htm
2019-12-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1447028/000000000019016815/0000000000-19-016815-index.htm
2020-07-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000089542120000423/0000895421-20-000423-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000089924319019548/0000899243-19-019548-index.htm
2019-01-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000004/0000903423-19-000004-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000012/0000903423-19-000012-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000288/0000903423-19-000288-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000298/0000903423-19-000298-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000299/0000903423-19-000299-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000093583619000122/0000935836-19-000122-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000093583620000133/0000935836-20-000133-index.htm
2018-12-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000104746918007755/0001047469-18-007755-index.htm
2019-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1447028/000104746919002498/0001047469-19-002498-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1447028/000104746920002560/0001047469-20-002560-index.htm
2018-12-20S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000110465918074106/0001104659-18-074106-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465918074112/0001104659-18-074112-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919006779/0001104659-19-006779-index.htm
2019-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919008025/0001104659-19-008025-index.htm
2019-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919023074/0001104659-19-023074-index.htm
2019-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919030387/0001104659-19-030387-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040421/0001104659-19-040421-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040422/0001104659-19-040422-index.htm
2019-07-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040589/0001104659-19-040589-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040594/0001104659-19-040594-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040598/0001104659-19-040598-index.htm
2019-07-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040934/0001104659-19-040934-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919045102/0001104659-19-045102-index.htm
2019-11-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919059987/0001104659-19-059987-index.htm
2019-12-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919070902/0001104659-19-070902-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465920020447/0001104659-20-020447-index.htm
2020-08-28S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1447028/000110465920100169/0001104659-20-100169-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001084/0001123292-18-001084-index.htm
2018-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001085/0001123292-18-001085-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001091/0001123292-18-001091-index.htm
2018-12-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001115/0001123292-18-001115-index.htm
2018-12-213Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001125/0001123292-18-001125-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000431/0001123292-19-000431-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000432/0001123292-19-000432-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000435/0001123292-19-000435-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000436/0001123292-19-000436-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000437/0001123292-19-000437-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000438/0001123292-19-000438-index.htm
2019-06-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000910/0001123292-19-000910-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000911/0001123292-19-000911-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000114420419034587/0001144204-19-034587-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000114420419034595/0001144204-19-034595-index.htm
2018-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318006281/0001171843-18-006281-index.htm
2018-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318006907/0001171843-18-006907-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318007089/0001171843-18-007089-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318007727/0001171843-18-007727-index.htm
2018-11-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318008152/0001171843-18-008152-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319001586/0001171843-19-001586-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319002996/0001171843-19-002996-index.htm
2019-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319004042/0001171843-19-004042-index.htm
2019-07-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319004412/0001171843-19-004412-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319005142/0001171843-19-005142-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184320007636/0001171843-20-007636-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000119312519193243/0001193125-19-193243-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000119312519193262/0001193125-19-193262-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000120919119041996/0001209191-19-041996-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000006/0001447028-19-000006-index.htm
2019-03-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000010/0001447028-19-000010-index.htm
2019-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000015/0001447028-19-000015-index.htm
2019-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000018/0001447028-19-000018-index.htm
2019-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000025/0001447028-19-000025-index.htm
2019-08-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000031/0001447028-19-000031-index.htm
2019-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000049/0001447028-19-000049-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000050/0001447028-19-000050-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000051/0001447028-19-000051-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000052/0001447028-19-000052-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000053/0001447028-19-000053-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000054/0001447028-19-000054-index.htm
2019-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000055/0001447028-19-000055-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000056/0001447028-19-000056-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000057/0001447028-19-000057-index.htm
2019-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000060/0001447028-19-000060-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000064/0001447028-19-000064-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000069/0001447028-19-000069-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000071/0001447028-19-000071-index.htm
2019-12-23S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1447028/000144702819000078/0001447028-19-000078-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000081/0001447028-19-000081-index.htm
2020-01-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000004/0001447028-20-000004-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000006/0001447028-20-000006-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000009/0001447028-20-000009-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000024/0001447028-20-000024-index.htm
2020-02-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000025/0001447028-20-000025-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000026/0001447028-20-000026-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000027/0001447028-20-000027-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000028/0001447028-20-000028-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000029/0001447028-20-000029-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000030/0001447028-20-000030-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000031/0001447028-20-000031-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000035/0001447028-20-000035-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000038/0001447028-20-000038-index.htm
2020-03-0610-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000041/0001447028-20-000041-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000043/0001447028-20-000043-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000046/0001447028-20-000046-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000049/0001447028-20-000049-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000052/0001447028-20-000052-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000063/0001447028-20-000063-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000064/0001447028-20-000064-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000065/0001447028-20-000065-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000066/0001447028-20-000066-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000067/0001447028-20-000067-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000068/0001447028-20-000068-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000069/0001447028-20-000069-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000071/0001447028-20-000071-index.htm
2020-06-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000073/0001447028-20-000073-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000078/0001447028-20-000078-index.htm
2020-07-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000080/0001447028-20-000080-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000100/0001447028-20-000100-index.htm
2020-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/0001447028-20-000118-index.htm
2020-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000121/0001447028-20-000121-index.htm
2020-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000124/0001447028-20-000124-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000126/0001447028-20-000126-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000129/0001447028-20-000129-index.htm
2020-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000135/0001447028-20-000135-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000140/0001447028-20-000140-index.htm
2020-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000143/0001447028-20-000143-index.htm
2020-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000144/0001447028-20-000144-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000150/0001447028-20-000150-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000149315219001945/0001493152-19-001945-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000149315220002406/0001493152-20-002406-index.htm
2018-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918001148/0001567619-18-001148-index.htm
2018-08-154/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918001171/0001567619-18-001171-index.htm
2018-10-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918003916/0001567619-18-003916-index.htm
2018-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918003919/0001567619-18-003919-index.htm
2018-10-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004374/0001567619-18-004374-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004376/0001567619-18-004376-index.htm
2018-10-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004378/0001567619-18-004378-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004380/0001567619-18-004380-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000162828018013909/0001628280-18-013909-index.htm
2020-01-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1447028/999999999520000069/9999999995-20-000069-index.htm
2020-10-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1447028/999999999520002943/9999999995-20-002943-index.htm
2020-07-23CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1447028/999999999720004141/9999999997-20-004141-index.htm
2020-09-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1447028/999999999720004563/9999999997-20-004563-index.htm

Arbutus Biopharma Corporation (ABUS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arbutus Biopharma Corporation (ABUS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2123%
Institutional Ownership: 3096%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-07-23Michael J. McElhaughChief Business OfficerSell20,000.005.01100,200.001,367,457.00https://www.sec.gov/Archives/edgar/data/1447028/000144702820000080/0001447028-20-000080-index.htm
2018-08-13Michael J. SofiaChief Scientific OfficerSell4,250.009.5140,435.781,499,153.00https://www.sec.gov/Archives/edgar/data/1447028/000156761918001148/0001567619-18-001148-index.htm
2018-11-28Mark J. MurrayDirectorBuy25,000.001.3533,750.00341,396.00https://www.sec.gov/Archives/edgar/data/1447028/000112329218001091/0001123292-18-001091-index.htm